Association Between Diagnosis-to-Ablation Time and Postablation Outcomes in Older Patients With Persistent Atrial Fibrillation

老年持续性房颤患者从诊断到消融的时间与消融术后结果之间的关联

阅读:1

Abstract

BACKGROUND: The relationship between the timing of catheter ablation and post-ablation outcomes in older patients with persistent atrial fibrillation (AF) remains uncertain. OBJECTIVES: This study aimed to investigate whether diagnosis-to-ablation time (DAT) influences post-ablation outcomes in older patients with persistent AF. METHODS: From January 2020 to December 2022, 587 patients were stratified into 2 groups: the early ablation group (DAT ≤12 months, n = 332) and the late ablation group (DAT >12 months, n = 255) based on DAT. The study outcomes included freedom from atrial arrhythmia (AA) recurrence and adverse cardiovascular outcomes (death, cardiovascular hospitalization, ischemic stroke, and a composite outcome comprising all 3 outcomes). RESULTS: The final analysis included 560 patients after 27 patients were lost to follow-up. After 24 months follow-up, 67.9% (216/318 patients) with the early ablation group were freedom from AA recurrence vs 59.1% (143/242 patients) in the late ablation group (HR: 0.68; 95% CI: 0.52-0.91; P = 0.005). Moreover, the late ablation group showed higher risks of the composite outcome (HR: 1.70; 95% CI: 1.23-2.34; P = 0.001) and cardiovascular hospitalization (HR: 1.57; 95% CI: 1.10-2.26; P = 0.011) compared with the early ablation group at 24-month follow-up. Ischemic stroke (HR: 1.87; 95% CI: 0.83-4.19; P = 0.126) and death (HR: 2.20; 95% CI: 0.54-8.93; P = 0.267) did not differ significantly between the 2 groups. CONCLUSIONS: In older patients with persistent AF, a DAT ≤12 months was associated with lower AA recurrence and lower risk of adverse cardiovascular outcomes, suggesting that early catheter ablation may improve clinical outcomes in this population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。